Experience and challenges from clinical trials with malaria vaccines in Africa

Malaria Journal

Case Study

Nahya Salim¹  Beverly Msambichaka¹  Tutu Mzee¹  Grace Mwangoka¹  Shubis Kafuruki¹  Maxmillian Mpina¹  Salim Abdulla¹  Seif Shekalaghe¹  Bernhards Ogutu²  Marcel Tanner³ 

[1] Ifakara Health Institute, Ifakara, Tanzania;Malaria Clinical Trials Alliance (MCTA), INDEPTH Network, Accra, Ghana;Swiss Tropical and Public Health Institute, Basel, Switzerland;

关键词: Malaria;    Vaccines;    Clinical trials;    Experiences;    Challenges;    Africa;   

DOI  :  10.1186/1475-2875-12-86

 received in 2012-10-10, accepted in 2013-02-28,  发布年份 2013

来源: Springer

【 摘 要 】

Malaria vaccines are considered amongst the most important modalities for potential elimination of malaria disease and transmission. Research and development in this field has been an area of intense effort by many groups over the last few decades. Despite this, there is currently no licensed malaria vaccine. Researchers, clinical trialists and vaccine developers have been working on many approached to make malaria vaccine available.African research institutions have developed and demonstrated a great capacity to undertake clinical trials in accordance to the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) standards in the last decade; particularly in the field of malaria vaccines and anti-malarial drugs. This capacity is a result of networking among African scientists in collaboration with other partners; this has traversed both clinical trials and malaria control programmes as part of the Global Malaria Action Plan (GMAP). GMAP outlined and support global strategies toward the elimination and eradication of malaria in many areas, translating in reduction in public health burden, especially for African children. In the sub-Saharan region the capacity to undertake more clinical trials remains small in comparison to the actual need.However, sustainability of the already developed capacity is essential and crucial for the evaluation of different interventions and diagnostic tools/strategies for other diseases like TB, HIV, neglected tropical diseases and non-communicable diseases. There is urgent need for innovative mechanisms for the sustainability and expansion of the capacity in clinical trials in sub-Saharan Africa as the catalyst for health improvement and maintained.

【 授权许可】

CC BY   
© Mwangoka et al.; licensee BioMed Central Ltd. 2013